Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity

 Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity

Alytas Therapeutics Signs an Agreement with Velabs Therapeutics to Develop Novel Immune-Based Therapy for Obesity

Shots:

  • Velabs and Alytas collaborated to jointly develop modulatory and functional Ab for a novel immune-based therapy against obesity utilizing Velabs’ microfluidic-based technology for rapid functional antibody screening
  • Velabs to receive royalties on the global sales of the products resulting from the collaboration. The collaboration focuses to develop a new treatment for obesity to reduce the global increase in associated co-morbidities such as diabetes and cardiovascular disease
  • Velab’s microfluidic technology tests millions of correctly paired human and mouse IgGs for therapeutic effects and is used for the screening of Ab with modulatory function on complex signaling proteins

Click here to­ read full press release/ article | Ref: Velabs Therapeutics | Image: Alytas Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post